sábado, 16 de marzo de 2013

Vidagliptina con metformina o con insulina disminuye los valores de HbA1C con riesgo de hipoglicemia disminuido.

Vildagliptin 50 mg bid added to insulin significantly reduced HbA1c in patients with T2DM inadequately controlled by insulin, with or without metformin. Vildagliptin was well tolerated, with a safety profile similar to placebo. These results were achieved without weight gain or an increase in hypoglycaemia incidence or severity in spite of improved glycaemic control.

No hay comentarios:

Publicar un comentario